Halozyme, Inc.

halozyme.com

Halozyme, Inc.
Halozyme is a biopharmaceutical company bringing disruptive solutions to significantly improve patient experiences and outcomes for emerging and established therapies. Halozyme advises and supports its biopharmaceutical partners in key aspects of new drug development with the goal of improving patients' lives while helping its partners achieve global commercial success.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Business Insights

IKTOS AND TEIJIN PHARMA TO CO-DEVELOP NEW TECHNOLOGY FOR SMALL MOLECULE DRUG DISCOVERY

Iktos | April 07, 2022

news image

Iktos, a company specialized in Artificial Intelligence for new drug design, and Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business that provides comprehensive healthcare services to improve the quality of life, today announced a strategic collaboration agreement in Artificial Intelligence for new drug design. Under the agreement, Iktos generative modelling technology will be implemented and applied to several Teijin Pharma’s small molecu...

Read More

Business Insights

AQEMIA ANNOUNCES AN EXTENSION OF ITS FIRST COLLABORATION WITH SANOFI ABOUT AI AND QUANTUM PHYSICS-DRIVEN DRUG DISCOVERY IN ONCOLOGY

Aqemia | June 16, 2022

news image

Aqemia, the next-gen pharmatech company leveraging artificial intelligence and quantum physics announced, today that it has entered a new research collaboration with Sanofi. This new agreement is a follow-up to a Research Collaboration initiated at the end 2020 by Sanofi to bring the unique technologies of Aqemia to the design and discovery of novel molecules in several projects in oncology, a priority therapeutic area for Sanofi. This initial collaboration resulted...

Read More

CORONAVIRUS TRACKER: GILEAD'S REMDESIVIR; WHITE HOUSE'S VACCINE PROJECT; PFIZER, BIONTECH'S VACCINE PROGRESS; ASTRAZENECA'S PIPELINE

Fiercepharma | April 29, 2020

news image

As headlines multiplied and analysts began sussing out Gilead Sciences' first controlled trial readout on remdesivir, NIAID director Anthony Fauci hailed the drug as real progress against the virus. Meanwhile, word emerged that the Trump administration is working up a Manhattan Project style vaccine initiative, bringing biotech, pharma and federal agencies together to speed up the work—and let the U.S. government take on the financial risks. Plus, Pfizer and BioNTech said they've d...

Read More

VALERITAS RECEIVES COURT APPROVAL OF SALE OF BUSINESS TO ZEALAND PHARMA

PR Newswire | March 20, 2020

news image

Valeritas Holdings, Inc.("Valeritas" or the "Company"), a medical technology company and maker of the V-Go® Wearable Insulin Delivery device, today announced that the U.S. Bankruptcy Court for the District of Delaware (the "Court") approved the sale of substantially all of the business to Zealand Pharma A/S (NASDAQ: ZEAL) ("Zealand"), a Denmark-based biotechnology company. The transaction is expected to be completed during the first week of April, subj...

Read More
news image

Business Insights

IKTOS AND TEIJIN PHARMA TO CO-DEVELOP NEW TECHNOLOGY FOR SMALL MOLECULE DRUG DISCOVERY

Iktos | April 07, 2022

Iktos, a company specialized in Artificial Intelligence for new drug design, and Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business that provides comprehensive healthcare services to improve the quality of life, today announced a strategic collaboration agreement in Artificial Intelligence for new drug design. Under the agreement, Iktos generative modelling technology will be implemented and applied to several Teijin Pharma’s small molecu...

Read More
news image

Business Insights

AQEMIA ANNOUNCES AN EXTENSION OF ITS FIRST COLLABORATION WITH SANOFI ABOUT AI AND QUANTUM PHYSICS-DRIVEN DRUG DISCOVERY IN ONCOLOGY

Aqemia | June 16, 2022

Aqemia, the next-gen pharmatech company leveraging artificial intelligence and quantum physics announced, today that it has entered a new research collaboration with Sanofi. This new agreement is a follow-up to a Research Collaboration initiated at the end 2020 by Sanofi to bring the unique technologies of Aqemia to the design and discovery of novel molecules in several projects in oncology, a priority therapeutic area for Sanofi. This initial collaboration resulted...

Read More
news image

CORONAVIRUS TRACKER: GILEAD'S REMDESIVIR; WHITE HOUSE'S VACCINE PROJECT; PFIZER, BIONTECH'S VACCINE PROGRESS; ASTRAZENECA'S PIPELINE

Fiercepharma | April 29, 2020

As headlines multiplied and analysts began sussing out Gilead Sciences' first controlled trial readout on remdesivir, NIAID director Anthony Fauci hailed the drug as real progress against the virus. Meanwhile, word emerged that the Trump administration is working up a Manhattan Project style vaccine initiative, bringing biotech, pharma and federal agencies together to speed up the work—and let the U.S. government take on the financial risks. Plus, Pfizer and BioNTech said they've d...

Read More
news image

VALERITAS RECEIVES COURT APPROVAL OF SALE OF BUSINESS TO ZEALAND PHARMA

PR Newswire | March 20, 2020

Valeritas Holdings, Inc.("Valeritas" or the "Company"), a medical technology company and maker of the V-Go® Wearable Insulin Delivery device, today announced that the U.S. Bankruptcy Court for the District of Delaware (the "Court") approved the sale of substantially all of the business to Zealand Pharma A/S (NASDAQ: ZEAL) ("Zealand"), a Denmark-based biotechnology company. The transaction is expected to be completed during the first week of April, subj...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us